Enantiomers of 2,3-dihydro-1,4-benzodioxine derivatives possessing both thrombin and fibrinogen GPIIb/IIIa binding inhibitory activities were prepared from (R)-and (S)-glycidol as potential dual antithrombotic compounds. The influence of chirality and substitution pattern on thrombin inhibition and on inhibition of fibrinogen binding to GPIIb/IIIa was analyzed. Docking studies were used in an attempt to rationalize the results. The (S)-isomers of both 2,3-dihydro-1,4-benzodioxine regioisomers at positions 6 and 7 were found to be better thrombin inhibitors than the corresponding (R)-enantiomers, whereas we observed that stereochemistry does not display a consistent influence on fibrinogen GPIIb/ IIIa binding inhibitory activity. Compound 11b, the (S)-isomer of the 6-substituted regioisomer, possessed the best balanced dual activity, with K i(thrombin) ¼ 1.67 AE 0.27 mM and IC 50(GPIIb/ IIIa) ¼ 0.665 AE 0.26 mM, raising the hope that merging anticoagulant and platelet antiaggregatory activities in the same molecule could lead to successful multitarget antithrombotic agents.
Introduction
Cardiovascular diseases are the main cause of death in developed countries [1] . Existing anticoagulant and antiplatelet therapy, despite its importance and effectiveness in the treatment of cardiovascular diseases, has numerous limitations such as bleeding, metabolism that differs in different individuals due to genetic polymorphism, and interaction with other drugs and food [2, 3] .
During the last decade much effort have been made to design novel anticoagulant drugs that target the coagulation enzymes thrombin, factor Xa, factor VII and factor IX, with the aim of obtaining a simple and satisfactory, orally applicable replacement for the existing warfarin treatment [4e11] . Ximelagatran, a prodrug of melagatran, was the first oral direct thrombin inhibitor introduced to the market, however it was withdrawn from the market in 2006 due to expressed hepatotoxicity [12, 13] . Dabigatran etexilate is a new oral prodrug for the direct thrombin inhibitor dabigatran ( Fig. 1 ) that entered the market in 2008 for the prevention of blood clotting following hip or knee surgery, and for the prevention of stroke in patients with non-valvular atrial fibrillation [14] . Good progress has also been made in the field of direct and indirect factor Xa inhibitors. Rivaroxaban, a recently introduced, highly selective oral factor Xa inhibitor, promised effectiveness and safety in preventing venous thromboembolism [15] . Other novel factor Xa inhibitors include the recently approved apixaban, and idraparinux that is in the final stage of clinical investigation [16] .
Platelets play an essential role in the maintenance of hemostasis; they are responsible for clot formation when damage of endothelium of blood vessels occurs [17] . The platelet glycoprotein IIb/IIIa antagonists abciximab, eptifibatide and tirofiban are potent antiplatelet agents, and are used to prevent pathological platelet aggregation in patients with acute coronary syndrome, heart attack and those undergoing invasive heart procedures [18] .
In clinical practice, an effective prophylaxis and treatment of thromboembolic diseases, such as deep vein thrombosis, thromboembolic stroke, pulmonary embolism and myocardial infarction, is achieved by using a combination of various antiaggregatory and anticoagulant drugs [19] . Since the combined use of thrombin inhibitors and glycoprotein IIb/IIIa antagonists in the prevention of cardiovascular diseases has shown additional benefits over treatment directed against thrombin or against platelets alone [20] , we envisaged merging anticoagulant and platelet antiaggregatory activity in the same molecule as a promising approach towards novel multitarget antithrombotic agents [21e25] . Recently, other groups have reported the preparation of dual anticoagulant/antiplatelet agents featuring high molecular weight, polysulfated conjugates [26] , in contrast to our dual acting compounds with strongly overlapping pharmacophores and low molecular weight.
In our previous work on potential dual antithrombotic compounds, combining in one molecule both thrombin inhibitory and fibrinogen receptor antagonistic activities [24, 25] , 3,4-dihydro-2H-1,4-benzoxazine [27] was selected as a suitable scaffold, on the basis of docking experiments, enabling convenient attachment of substituents in positions 2, 4, 6 and 7 [25] . The benzamidine moiety, a typical P1 group of thrombin inhibitors and an arginine mimetic of the RGD motif [28] , was attached at position 2 of the benzoxazine core, while P3 benzyl and carboxylic acid moieties, required for thrombin inhibition and GPIIb/IIIa binding [29] , were bound at positions 6 or 7 of the 1,4-benzoxazine skeleton (Fig. 1 ). Molecular modeling studies predicted 7-isomers to be better thrombin inhibitors while 6-isomers were expected to possess better inhibition of fibrinogen GPIIb/IIIa binding, as was later confirmed in biological assays [25] . Focusing on optimization of the P3 part, with a combination of different aromatic and carboxylate group moieties, we succeeded in preparing well-balanced dual compounds with thrombin K i values and IC 50 values for inhibition of fibrinogen binding to platelet GPIIb/IIIa in the high nanomolar/low micromolar ranges [30] . Replacement of the highly basic benzamidine moiety with the less basic [1, 2, 4] triazolo [4,3-b] pyridazine-6-yl group resulted in loss of both thrombin inhibitory and fibrinogen receptor antagonistic activities [31] , showing the importance of the benzamidine group for binding to both targets. The failure to achieve better affinities of the designed compounds for thrombin and fibrinogen receptor demonstrates the difficulty in reaching a compromise that would meet the constraints imposed by both binding sites.
When designing multiple ligands with highly overlapping pharmacophores, balancing activities for both targets is demanding, so all structural information is of the utmost value [32e35]. In the present work we report a 1,4-benzodioxine series of enantiomeric compounds that combine, in the same molecule, highly overlapping pharmacophores of thrombin inhibitors and fibrinogen receptor antagonists ( Fig. 1 ). They resulted from replacement of the 1,4-benzoxazine core by a 1,4-benzodioxine scaffold [36] , a privileged heterocyclic skeleton applied in the design of selective a 1 adrenoceptor antagonists [37] , antioxidants [38, 39] , radical scavenging compounds [40e42], hypolipidemic [43] and antiinflammatory agents [44, 45] . In order to explore the significance of chirality and regioisomerism in balancing the activity of the new 1,4-benzodioxine compounds at both targets, and thanks to the commercial availability of both (R)-and (S)-glycidol (required for enantioselective synthesis of the parent 2-substituted benzodioxine cores), we prepared both enantiomers of the benzodioxine 6and 7-regioisomers and studied the effects of chirality and regioisomerism on binding the resulting potential dual antithrombotic compounds to thrombin and platelet fibrinogen receptor.
Chemistry
The synthesis of target 1,4-benzodioxine enantiomers 11ae d from 4-nitrocatechol is presented in Schemes 1 and 2. The strongly electronegative nitro group in 4-nitrocatechol enabled effective control of the regioselectivity in construction of the 1,4- Structures of the clinically used thrombin inhibitor dabigatran, the racemic 1,4benzoxazine derivatives [25, 30] and the enantiomers of 1,4-benzodioxine derivatives reported in this paper.
benzodioxine ring and, depending on the applied base, gave rise to 6-and 7-nitro isomers, respectively [46] . Thus, using a modified published procedure for the synthesis of the racemates [47] , the reaction of 4-nitrocatechol with (R)-and (S)-(2-tosyloxymethyl) oxirane (3b and 3a), in the presence of potassium carbonate in N,N-dimethylformamide afforded enantiomers of (7-nitro-2,3dihydro-1,4-benzodioxin-2-yl)methanol (5d and 5c), whereas the reaction of 4-nitrocatechol with 3a or 3b, using sodium hydride as a base, gave (R)-and (S)-6-nitro isomers 5a and 5b (Scheme 1). Both nitro isomers of the (R)-and (S)-series were reacted with 4-hydroxybenzonitrile under Mitsunobu conditions to give ethers 6aed, which were reduced in the next step to amines 7aed, using catalytic hydrogenation over palladium on charcoal. These were benzylated, using benzaldehyde and sodium borohydride, and the resulting N-benzylamines 8aed acylated with ethyl oxalyl chloride to give compounds 9aed. Upon Pinner reaction they afforded esters 10aed which, after alkaline hydrolysis with lithium hydroxide in methanol/tetrahydrofuran, gave the enantiomeric carboxylic acids 11aed (Scheme 2). We tried to develop an HPLC method for determining the enantiomeric purity of products 5e11, but succeeded only with compounds 8aed for which an enantiomeric excess >95% was obtained. The nonracemizing conditions in the last two reaction steps and consistent optical rotation values of the products allow the conclusion that the enantiomeric excess of compounds 10aed and 11ae d remained higher than 95%. 
Reagents and conditions

Biological results
Compounds 10aed and 11aed, comprising enantiomers of the 6-and 7-isomers, were tested for inhibition of thrombin and, in order to assess their selectivity for related serine proteases, also for inhibition of factor Xa and trypsin. Additionally, they were tested for inhibition of fibrinogen binding to GPIIb/IIIa. The results are presented in Table 1 . The general structureeactivity relationship which was observed in the 1,4-benzoxazine series can also be seen in the case of the 1,4-benzodioxine series. Esters 10aed were found to be more potent thrombin inhibitors than the corresponding carboxylic acids 11aed, but they lacked fibrinogen GPIIb/IIIa binding activity (IC 50 > 200 mM). Compounds bearing a P3 moiety in position 6 (11aeb) displayed more pronounced fibrinogen GPIIb/ IIIa binding inhibitory activity (IC 50 0.66 and 1.21 mM), while compounds bearing a P3 moiety at position 7 exhibited more pronounced thrombin inhibitory activity (K i ¼ 0.078e2.69 mM).
While compounds 10aed and 11aed were not selective towards two similar serine proteases, trypsin and factor Xa, the compound with the most potent thrombin inhibitory activity (10d) was found also to be the most selective. As demonstrated in Fig. 1 , compound 11b, the (S)-isomer of the 6-substituted regioisomer, possessed the best balanced dual activity (K i(thr) ¼ 1.67 AE 0.27 mM, IC 50(GPIIb/ IIIa) ¼ 0.665 AE 0.26 mM). Compound 10d, the (S)-isomer of the 7-regioisomer, is the most potent thrombin inhibitor, with K i(thr) ¼ 77.8 AE 5.0 nM, and compound 11b, ((S)-isomer of the 6regioisomer) has the most potent fibrinogen GPIIb/IIIa binding inhibitory activity, with IC 50(IIb/IIIa) ¼ 665 AE 260 nM. This demonstrates that, in the development of dual antithrombotic compounds based on the 1,4-benzodioxine scaffold, optimizing fibrinogen receptor activity is a more difficult task than optimizing thrombin inhibition.
The (S)-isomers of the 6-and 7-series were found to be better thrombin inhibitors than the (R)-isomers. Overall, these results are comparable with those for the 1,4-benzoxazine analogues. The racemic 1,4-benzoxazine derivative substituted at position 6 showed higher activity on both targets (K i(thr) ¼ 0.62 AE 0.10 mM, IC 50(GPIIb/IIIa) ¼ 2.8 AE 1.5 mM), while the racemic 1,4-benzoxazine derivative substituted at position 7 had more pronounced thrombin inhibitory activity (K i(thr) ¼ 0.19 AE 0.02 mM, IC 50(GPIIb/ IIIa) ¼ 39 AE 18 mM) [26] . When considering eudismic ratios, the results in Table 1 demonstrate that, in the case of esters 10aed in the 6-regioisomer series, the (S)-isomer is 3.8 times more potent and, in the 7-regioisomer series, 8.7 times more potent thrombin inhibitor than corresponding (R)-isomer. Similar results are seen in the case of acids 10aed where, in 6-substituted compounds, the (S)-isomer is 3.1 times more potent and, in the 7-substituted compound, 10.1-fold more potent as a thrombin inhibitor. Stereochemistry does not appear to have such a consistent influence on fibrinogen GPIIb/IIIa binding inhibitory activity. In the case of the 6substituted compound, the (S)-isomer 11b is 1.8 times more potent than the (R)-isomer 11a, while in case of 7-substituted compounds the (R)-isomer 11c is 2.4 times more potent than the (S)-isomer 11d. It can thus be concluded that, in the 1,4-benzodioxine series, the (S)-6-isomers offer the best opportunities for optimization towards balanced dual acting compounds.
Docking studies
In an attempt to rationalize the differences in the binding affinities of (R)-and (S)-enantiomers for thrombin and fibrinogen receptor, we performed docking of compounds 11a and 11bboth enantiomers of the more balanced 6-regioisomer docked to the thrombin active site and to the binding site of GPIIb/IIIa are depicted in Fig. 2 . Given the similarity of our compounds to dabigatran, the crystal structure of the dabigatranethrombin complex (PDB: 1KTS) [48] was used for docking experiments. Compounds 11a and 11b bind to the thrombin active site in a similar manner to dabigatran but the configuration at chiral centers slightly influences the difference in their binding modes. The distance between the C-atoms of the Asp189 carboxylate and the amidine group is 3.9 Å and 4.0 Å for 11a and 11b, and two hydrogen bonds connect the amidine hydrogens and carboxylate oxygen atoms. Additional hydrogen bonds of 1.98 Å and 2.0 Å between the benzamidine and the Gly219 backbone for the two compounds are observed. The 2,3-dihydro-1,4-benzodioxine scaffold is located in the S2 binding pocket and the benzyl group reaches into the lipophilic S3 binding pocket, with the P3 carboxylate stretching outwards from the thrombin surface. The methyleneoxy groups adjacent to the chiral carbon of 3,4-dihydro-1,4-benzodioxine are oriented differently in the two enantiomers. The distance between the oxygen of the methyleneoxy group and the Ser195 OH group (OeHO) is 3.1 Å in 11b and 3.6 Å in 11a. The carbon atom of the methylenoxy groups adjacent to the chiral center is the atom that differs most in its positioning in 11a and 11bby 1.92 Å. In 11b, the methylene group is closer to the protein surface while, in 11a, it points outwards from the thrombin surface.
The analysis of the binding modes of 11a and 11b docked in the binding site of GPIIb/IIIa (using PDB: 2VDMthe only published crystal structure of GPIIb/IIIa in a complex with a low molecular weight RGD mimetic) [49] shows that the compounds take an extended conformation. The carboxylic acid moiety occupies an identical location in 11a and 11b, making electrostatic interactions with the Mg 2þ atom and hydrogen-bonding to the amide proton of In summary, the measured activities and analysis of the docking positions of 11a and 11b at the two targets lead to the conclusion that the configuration at the chiral center, and the consequent different positioning of the methylenoxy moiety, accounts, at least partly, for the difference in potency of the two enantiomers. Whereas the methylenoxy moiety situated in close proximity to the chiral center is required for flexibility of the molecule (compounds 10ae11d adopt a bent shape in the thrombin active site and extended conformations in the fibrinogen receptor-binding site), this could also explain the low eudismic ratios resulting from the e CH 2 Oe group imposed molecular flexibility that diminishes the difference between the binding conformations of two enantiomers at a particular target.
Conclusion
A novel 1,4-benzodioxine enantiomeric series of compounds have been prepared that act both as thrombin inhibitors and as fibrinogen GPIIb/IIIa binding inhibitors. The influence of chirality and regioisomerism on their thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities has been analyzed. The differences in potency of isomers and observed eudismic ratios can be explained in terms of the docking poses of the two stereoisomers. Unfortunately, we were not able to observe antithrombotic action of this series of compounds in in vivo model of venous thrombosis in rat, indicating that their potencies on both targets are still too weak to be measured in vivo. The attempt to balance thrombin inhibition and fibrinogen GPIIb/IIIa binding inhibitory activities on the one hand and to achieve lower nanomolar K i (thrombin) and IC 50 (GPIIb/IIIa) values on the otherwhich could result in in vivo antithrombotic activityremains a viable, but highly demanding challenge in the search for effective dual antithrombotic drugs.
Experimental section
General
Chemicals were obtained from Acros, Aldrich Chemical Co. and Fluka and used without further purification. Analytical TLC was performed on silica gel Merck 60 F 254 plates (0.25 mm), using visualization with ultraviolet light. Column chromatography was carried out on silica gel 60 (particle size 240e400 mesh). Melting points were determined on a Reichert hot stage microscope and are uncorrected. 1 H NMR and 13 C NMR spectra were recorded on a 400 MHz Bruker AVANCE III NMR spectrometer ( 1 H NMR at 400.13 MHz and 13 C NMR at 100.61 MHz) and on a Bruker Avance DPX300 spectrometer ( 1 H NMR at 300 MHz, 13 C NMR at 75 MHz) in DMSO-d 6 solution, with TMS as internal standard. 13 C NMR spectra were assigned using gradient COSY, HSQC and HMBC experiments. The following abbreviations were used to describe peak splitting patterns wherever appropriate: br
IR spectra were recorded on a PerkineElmer 1600 FT-IR spectrometer. Microanalyses were performed on a PerkineElmer C, H, N Analyzer 240 C. Analyses indicated by the symbols of the elements were within AE0.4% of the theoretical values. Mass spectra were obtained using a VG-Analytical Autospec Q mass spectrometer. Optical rotations were measured on a PerkineElmer 1241 MC polarimeter. Reverse phase HPLC was performed on an Agilent Technologies HP 1100 instrument with G1365B UVevis detector (254 nm), using an Eclipse Plus C18 column 5 mm (4.6 Â 150 mm) at flow rate of 1 mL/min. The eluent was a mixture of 0.1% TFA in water (A) and methanol (B) and the gradient was 40% B to 80% B in 15 min. Chiral HPLC analyses were performed on a JASCO ChromPass Software Version 1.8 with JASCO UV-2075 UVevis detector (244 nm), using a Chiralcel OJ-H 5 mm 4.6 Â 250 mm column at flow rate of 1 mL/min. Compounds were separated under isocratic conditions using as eluent a mixture of 60% n-hexane and 40% ethanol. All the compounds reported in this paper were >95% pure. Esters 10aed were purified by reverse phase column chromatography, using a Flash Purification System ISOLERAÔ. The eluent was a mixture of 0.1% TFA in water (A) and methanol (B) and the gradient was 40% B to 80% B in 30 column volumes.
Synthesis of (R)-glycidyl tosylate (3b)
To a solution of (S)-glycidol (5.50 g, 74.24 mmol), triethylamine (8.26 g, 81.66 mmol) and 4-(dimethylamino)pyridine (2%, 181 mg, 1.48 mmol) in 60 mL dichloromethane at 0 C, tosyl chloride (14.15 g, 74.24 mmol) was added and the mixture was stirred at room temperature for 3 h with formation of a white precipitate. Dichloromethane (40 mL) was added and the mixture was subsequently washed with 100 mL 5% aq. K 2 CO 3 , 100 mL 1 M HCl, and 100 mL water. The organic layer was dried over Na 2 SO 4 , filtered and evaporated to dryness. The crude product (15.56 g colourless oil, 92% yield) was used in the next step without further purification; 
Synthesis of (S)-glycidyl tosylate (3a)
To a solution of (R)-glycidol (4.00 g, 54.00 mmol), triethylamine (6.01 g, 59.50 mmol) and 4-(dimethylamino)pyridine (2%, 132 mg, 1.08 mmol) in 50 mL dichloromethane at 0 C, tosyl chloride (10.30 g, 54.00 mmol) was added and the mixture was stirred at room temperature for 1 h. During stirring a white precipitate was formed. The reaction mixture was subsequently washed with 100 mL 5% aq. K 2 CO 3 , 100 mL 1 M HCl, and 100 mL water. The organic layer was dried over Na 2 SO 4 , filtered and evaporated to dryness. The crude product (11.63 g colourless oil, 95% yield) was used in the next step without further purification; [a] D ¼ þ16.3 (c ¼ 0.57, CHCl 3 ), lit.: [51] [a] D ¼ þ17. 5 
To a suspension of NaH (60% dispersion, 120 mg, 1.5 mmol) in 5 mL DMF at 0 C, 4-nitrocatechol (310 mg, 2.00 mmol) in 1 mL DMF was added carefully. The mixture was stirred at 0 C for 30 min (until gas formation ceased) and then a solution of (S)-glycidyl tosylate (502 mg, 2.20 mmol) in 1 mL DMF was added. The reaction mixture was stirred at room temperature for 30 min and then heated at 80 C for 2 h. Upon cooling, the mixture was poured onto 15 mL water. The mixture was extracted with 3 Â 20 mL diethyl ether. The combined organic phases were dried over Na 2 SO 4 , filtered and evaporated to dryness. The crude product obtained was purified by column cromatography (petrolether:ethyl acetate 1:1) to give 178 mg (42%) of pale yellow crystals; mp 112e114 C; To a suspension of NaH (60% dispersion,120 mg,1.5 mmol) in 5 mL DMF at 0 C, 4-nitrocatechol (310 mg, 2.00 mmol) in 1 mL DMF was added. The mixture was stirred at 0 C for 30 min (until gas formation ceased) and then a solution of (R)-glycidyl tosylate (502 mg, 2.20 mmol) in 1 mL DMF was added. The reaction mixture was stirred at room temperature for 30 min and then heated at 80 C for 2 h. Upon cooling, the mixture was poured onto 15 mL water. The mixture was extracted with 3 Â 20 mL diethyl ether. The combined organic phases were dried over Na 2 SO 4 , filtered and evaporated to dryness. The crude product obtained was purified by column cromatography (petrolether:ethyl acetate To a solution of compound 6a (800 mg, 2.56 mmol) in 100 mL MeOH, 10% Pd/C (80 mg) was added and the mixture was stirred in a hydrogenator at 25 bar for 1 h till the reaction was completed. The catalyst was filtered off and the solvent was evaporated in vacuo to yield 720 mg (100%) of 7a which was used in the next step without purification. To a solution of the crude amine 7a (722 mg, 2.56 mmol) in methanol (50 mL) containing molecular sieves under argon atmosphere, benzaldehyde (406 mg, 3.83 mmol) was added and the mixture was stirred at room temperature for 12 h, until the aldimine formation was completed. The reaction mixture containing aldimine in methanol was carefully treated with NaBH 4 (154 mg, 4.08 mmol) and stirred for additional 1 h, filtered, and the solvent was evaporated in vacuo. The crude residue was dissolved in dichloromethane (50 mL) and washed successively with saturated NaHCO 3 solution (3 Â 50 mL) and brine (1 Â 50 mL). The organic phase was dried over Na 2 SO 4 and the solvent evaporated under reduced pressure. The oily product was purified by column chromatography using dichloromethane as eluant to obtain 439 mg (46%) of 8a as yellow crystals; mp 144e147 C; [a] D ¼ þ32.4 Gaseous HCl was slowly introduced over 30 min into a solution of the nitrile 9a (480 mg, 1.02 mmol) in anhydrous ethanol (30 mL). The reaction mixture was closed tightly and stirred for 24 h at room temperature. The solvent was evaporated in vacuo and the residue washed 3 times with anhydrous diethyl ether. Obtained iminoether was dissolved in anhydrous EtOH (30 mL), ammonium acetate (3 eq, 237 mg, 3.06 mmol) was added and the reaction mixture stirred for 24 h at room temperature. The solvent was evaporated and crude product was purified by reverse phase column chromatography with gradient using methanol/trifluoroacetic acid (40e80% in 30 min) as eluant. After evaporation of methanol white crystals were precipitated from trifluoroacetic acid, filtered off and dried to yield 350 mg (70%) of 10a as a white powder; yield 350 mg (58%); mp 188e191 C; [a] D ¼ þ31.4 (c ¼ 0.5, EtOH); 1 To a solution of 10a (150 mg, 0.31 mmol) in a mixture of tetrahydrofuran (3 mL) and methanol (1 mL), 1 M LiOH (1.50 mL, 1.50 mmol) was added and the reaction mixture stirred at room temperature for 1 h. The solvents was evaporated in vacuum and the resulting aqueous solution neutralized with 0.1% trifluoroacetic acid until the product started to precipitate (pH ¼ 2). The product was filtered off and dried to obtain 79 mg (68%) of 11a as a white powder; mp 290e293 C; [a] D ¼ þ59. 6 13 
Docking studies
The binding modes of the ligands to both targets were studied by Autodock 4.0 [53] . The energetically most favorable conformation was found for each stereoisomer with HyperChem, using the semiempirical method MNDO. All amide bonds had trans configuration and were marked as non-rotatable. Compounds were protonated on the basic center (amidino, or amino group) and were assigned with a negative charge on the acidic center (carboxylic group). The crystal structures of thrombin (PDB entry code: 1KTS) [48] and GP IIb/IIIa (PDB entry code: 2VDM) [49] were extracted from the Brookhaven Protein Database. The PDB crystal structures were prepared for docking by removing water molecules and ligands. In the case of 2VDM, the magnesium ion in the active site was retained and manually assigned a charge of þ2 and solvation parameters. The ligands were docked into a restricted box centered in the active site (22 Å Â 22 Å Â 22 Å). For the global search using the LGA (Lamarckian genetic algorithm), the size of the initial random population was 250 individuals, the maximal number of energy evaluations 1.25 Â 10 6 , the maximal number of generations 500, the number of top individuals that survived into the next generation (the elitism) 1, the probability that a gene would undergo a random change 0.02, and the crossover probability 0.80. The average of the worst energy was calculated over a window of 10 generations. For a purely local search, the pseudo Solis and Wets method was used, whereas the Solis and Wets method was used for the LGA part of the local search. The parameters used for local search in both cases were a maximum of 1000 iterations per local search, the probability of performing a local search on an individual was 1.0, the maximal number of consecutive successes or failures before doubling or halving the step size of the local search was 4, and the lower bound on the step size, 0.01, was the termination criterion for the local search. A total of 250 dockings were performed, and ligands with RMSD less than 1 were joined in clusters. The ligand with the lowest docked energy was chosen for interpreting the docking results.
Biochemical evaluation
Enzyme assay for inhibition of serine proteases
The enzymic amidolytic method for determining inhibition of thrombin, factor Xa and trypsin was based on the spectrophotometric determination of absorbance of the product formed after amide bond cleavage of a chromogenic substrate in the presence of the enzyme. K i , which is a quantitative measure of inhibitor potency, was determined from the kinetics of substrate hydrolysis with and without the addition of the inhibitor. Measurements (spectrophotometer, BioTek Synergy H4) were performed in 96-well microtiter Trypsin was assayed at a final concentration of 0.5 nkat/mL using the substrate S-2222 (Chromogenix) at 50 and 100 mM final concentrations. Inhibitors were dissolved in DMSO (concentration of stock solutions, 10 mmol/L) and diluted with distilled water to concentrations from 0.5 to 100 mM. Reaction rates were measured in the presence and the absence of the inhibitor. Then 50 mM HBSA buffer, the 50 mM solution of each inhibitor concentration (or of HBSA buffer in case of measurement without inhibitor), and 50 mM of enzyme solution were pipetted into the microtiter wells. The plate was incubated for 15 min at 25 C and 50 mL of chromogenic substrate then added. Absorbance at 405 nm was measured every 10 s at 25 C. Measurements were carried out in triplicate with three concentrations of the inhibitor and two concentrations of the substrate. For every combination of concentrations, K i was calculated from the change of absorbance in the initial, linear part of the curve according to the method of Cheng and Prusoff [54] and the final result was given as their average value. Dabigatran (thrombin, K i ¼ 6.3 AE 1.1 nM) was used as control.
6.29.2. Inhibition of in vitro binding of fibrinogen to isolated GPIIb/ IIIa and GPV/IIIa receptors Binding affinities to GPIIb/IIIa and GPV/IIIa receptor were measured by a solid-phase competitive displacement assay. Human fibrinogen (100 mg) was dissolved in aqueous NaCl (0.3 M, 5 mL) at 30 C and then it was diluted with 0.1 M NaHCO 3 in water to a final concentration of 1 mg/mL. Biotin N-hydroxysuccinimide ester (2 mg) was dissolved in DMF (2 mL) and added to 6 mL of fibrinogen solution. The reaction mixture was incubated for 90 min at 30 C and dialyzed for 3 h at room temperature against buffer 1 (3 L, 20 mM Tris, 150 mM NaCl, pH 7.4). After dialysis, the solution was centrifuged for 5 min at 5400 rpm and Tween-20 (0.005%) added to give the stock solution. Human integrin (10 mL of GPIIb/IIIa receptor solution (Calbiochem), 1 mL of GPV/IIIa receptor solution (Calbiochem)) was diluted in 10.2 mL of buffer 2 (50 mM Tris, 150 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnCl 2 , pH 7.4) and adsorbed to 96well (100 mL/well) high-binding microtiter plates (Greiner, Lumitrac 600) overnight at 4 C. Nonspecific receptor-binding sites were blocked with 1% BSA in buffer 2 (200 mL/well). Following incubation for 1 h at room temperature, the plates were washed twice with buffer 3 (buffer 2 containing 0.1% Tween-20). The potential antagonists were serially diluted with buffer 2 containing 0.1% of BSA and test solutions added (50 mL/well) together with biotinylated fibrinogen (50 mL/well, 1:42 dilution of stock solution in buffer 2 containing 0.1% of BSA) to each well. The plates were incubated for 2 h at room temperature, and then washed twice with buffer 3.
Peroxidase-conjugated antibiotin goat antibody (100 mL/well of a 1:1000 dilution of purchased solution (Calbiochem) in buffer 2 containing 0.1% of BSA) was added to each well and incubated for another hour. The microtiter plates were washed three times with buffer 3. Finally, chemiluminescent substrate (POD, Roche Diagnostics, Boehringer Mannheim) (100 mL/well) was added and the luminescence measured with a BioTek Synergy H4 multimode research reader three times over 10 min. Positive controls received no inhibitors, while negative controls received no receptor. Tirofiban (IC 50(GPIIb/IIIa) ¼ 0.37 AE 0.11 nM) was used as the internal standard. Assays were performed in duplicate and repeated at least three times on various days. The mean experimental data were fitted to the sigmoid model and IC 50 values calculated from the doseeresponse curve.
